Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash & Current Investments: 2020-2025

Historic Cash & Current Investments for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $91.6 million.

  • Xeris Biopharma Holdings' Cash & Current Investments rose 31.98% to $91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $280.9 million, marking a year-over-year decrease of 8.42%. This contributed to the annual value of $71.6 million for FY2024, which is 1.15% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Cash & Current Investments is $91.6 million, which was up 54.50% from $59.3 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Cash & Current Investments registered a high of $132.1 million during Q1 2022, and its lowest value of $58.4 million during Q1 2025.
  • Its 3-year average for Cash & Current Investments is $75.4 million, with a median of $72.5 million in 2023.
  • In the last 5 years, Xeris Biopharma Holdings' Cash & Current Investments spiked by 145.43% in 2021 and then plummeted by 40.60% in 2023.
  • Xeris Biopharma Holdings' Cash & Current Investments (Quarterly) stood at $102.4 million in 2021, then grew by 19.07% to $122.0 million in 2022, then slumped by 40.60% to $72.5 million in 2023, then decreased by 1.15% to $71.6 million in 2024, then soared by 31.98% to $91.6 million in 2025.
  • Its last three reported values are $91.6 million in Q3 2025, $59.3 million for Q2 2025, and $58.4 million during Q1 2025.